What is the next step in medical innovation that has fallen into the "prisoner's dilemma"?

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'> How should China's pharmaceutical innovation continue?

How should China's pharmaceutical innovation continue?544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>First, we must call on traditional chemical pharmaceutical companies to accelerate the pace of transformation of biopharmaceuticals.
Biopharmaceuticals bring new drug action mechanisms or new targets for diseases that cannot be made or treated in the past.
This opens the door to the development of highly profitable innovative drugs, and it will last for a period of time (maybe 30 years).
The bonus of the times when molecular biology enters the pharmaceutical field.
First, we must call on traditional chemical pharmaceutical companies to accelerate the pace of transformation of biopharmaceuticals.
Biopharmaceuticals bring new drug action mechanisms or new targets for diseases that cannot be made or treated in the past.
This opens the door to the development of highly profitable innovative drugs, and it will last for a period of time (maybe 30 years).
The bonus of the times when molecular biology enters the pharmaceutical field.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The data also proves that the transfer of medicines from small molecules to biological agents is getting faster and faster.
From 2003 to 2015, the proportion of biologics in 12 years only increased by 5.
3%; and from 2015 to 2020, the proportion of biologics in 5 years increased by 1 trillion US dollars, and the market share climbed from 13.
8% to 33.
6%.
Correspondingly, the market share of small molecule drugs dropped to 59.
9% over the same period.
The data also proves that the transfer of medicines from small molecules to biological agents is getting faster and faster.
From 2003 to 2015, the proportion of biologics in 12 years only increased by 5.
3%; and from 2015 to 2020, the proportion of biologics in 5 years increased by 1 trillion US dollars, and the market share climbed from 13.
8% to 33.
6%.
Correspondingly, the market share of small molecule drugs dropped to 59.
9% over the same period.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>If you enter the biopharmaceutical field now, there will not be such a big gap between domestic and foreign, large and small, traditional and innovative pharmaceutical companies (such as large, high-quality high-throughput compound libraries for screening of millions of physical molecules).
Compete with major international pharmaceutical companies globally.
If you miss the opportunity given to this industry by the times, the company will lose a good opportunity to grow and develop.
If you enter the biopharmaceutical field now, there will not be such a big gap between domestic and foreign, large and small, traditional and innovative pharmaceutical companies (such as large, high-quality high-throughput compound libraries for screening of millions of physical molecules).
Compete with major international pharmaceutical companies globally.
If you miss the opportunity given to this industry by the times, the company will lose a good opportunity to grow and develop.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>01 Only pharmaceutical companies with international and domestic market competitiveness can survive and develop 01 Only pharmaceutical companies with international and domestic market competitiveness can survive and develop 01 Only pharmaceutical companies with international and domestic market competitiveness can survive and develop 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The enlightenment from the 2020 new pulmonary crown epidemic is that drug research, the pharmaceutical industry, and human health are closely related.
Keeping up with the times lies not only in solving employment and developing the economy, but also a sign of social stability and people's happiness.
The enlightenment from the 2020 new pulmonary crown epidemic is that drug research, the pharmaceutical industry, and human health are closely related.
Keeping up with the times lies not only in solving employment and developing the economy, but also a sign of social stability and people's happiness.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Although small molecule drugs are still an important area of ​​drug research and development, biomacromolecule drugs, especially targeted biologic drugs, have a high success rate and can achieve better curative effects on diseases that were previously uncurable or have poor therapeutic effects.
A large part of the income of large international pharmaceutical companies in recent years has come from biopharmaceuticals, and the trend of strategic transformation of biopharmaceuticals is very obvious: From 2021 to 2026, the global biopharmaceutical market will reach US$505 billion, accounting for 35% of the total pharmaceutical market.
Of the 10 best-selling drugs in the world in 2019, 6 are already macromolecular biologics.
The number one drug is AbbVie's anti-TNFα monoclonal antibody Humira (Humira), which has won the sales champion for eight consecutive years.
Although small molecule drugs are still an important area of ​​drug research and development, biomacromolecule drugs, especially targeted biologic drugs, have a high success rate and can achieve better curative effects on diseases that were previously uncurable or have poor therapeutic effects.
A large part of the income of large international pharmaceutical companies in recent years has come from biopharmaceuticals, and the trend of strategic transformation of biopharmaceuticals is very obvious: From 2021 to 2026, the global biopharmaceutical market will reach US$505 billion, accounting for 35% of the total pharmaceutical market.
Of the 10 best-selling drugs in the world in 2019, 6 are already macromolecular biologics.
The number one drug is AbbVie's anti-TNFα monoclonal antibody Humira (Humira), which has won the sales champion for eight consecutive years.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>In contrast, my country's innovative biological drugs are rarely original.
Many large pharmaceutical companies innovate mainly through new drug introduction (license-in), expired patent drug imitation, Me-too, Me-better, etc.
, and the introduction of project products Most of them only have the commercialization rights of the drug in Greater China, which not only introduces high prices, but also grants authorized parties a certain percentage of sales.
These "micro-innovations" can be targeted to supplement product lines, shorten the development cycle of innovative drugs, and quickly meet the needs of patients, especially when there are relatively few varieties, which can ensure considerable benefits.
In contrast, my country's innovative biological drugs are rarely original.
Many large pharmaceutical companies innovate mainly through new drug introduction (license-in), expired patent drug imitation, Me-too, Me-better, etc.
, and the introduction of project products Most of them only have the commercialization rights of the drug in Greater China, which not only introduces high prices, but also grants authorized parties a certain percentage of sales.
These "micro-innovations" can be targeted to supplement product lines, shorten the development cycle of innovative drugs, and quickly meet the needs of patients, especially when there are relatively few varieties, which can ensure considerable benefits.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The introduction of innovative drug technology is equivalent to a "joint venture car", and generic drugs are a "domestic car".
The Santana is not an innovative model for Volkswagen, but the introduction of domestic vehicles is not only an innovation, but also does not prevent making a lot of money in the Chinese market; the "joint venture car" with expanded indications can also be exported (license-out).
Innovative momentum, and profitability to a higher level.
The introduction of innovative drug technology is equivalent to a "joint venture car", and generic drugs are a "domestic car".
The Santana is not an innovative model for Volkswagen, but the introduction of domestic vehicles is not only an innovation, but also does not prevent making a lot of money in the Chinese market; the "joint venture car" with expanded indications can also be exported (license-out).
Innovative momentum, and profitability to a higher level.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Under such expectations, many generic biopharmaceutical start-up companies have been enthusiastically praised and fueled by the capital market, leading to an obvious high-level duplication of biopharmaceutical innovation in my country: PD-1/PD-L1 target-related drugs exceed 260 There are 115 clinical trials, and there are more than 100 companies in the country with PD-1/L1 products.
Under such expectations, many generic biopharmaceutical start-up companies have been enthusiastically praised and fueled by the capital market, leading to an obvious high-level duplication of biopharmaceutical innovation in my country: PD-1/PD-L1 target-related drugs exceed 260 There are 115 clinical trials, and there are more than 100 companies in the country with PD-1/L1 products.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>However, in order to promote the truly innovative development of the pharmaceutical industry and improve the international competitiveness of domestic drugs, the state began to implement centralized procurement and medical insurance negotiations at the end of 2018, completely subverting the operation model of the imitation and innovative drug market in China’s pharmaceutical industry, especially at the end of December 2020.
Medical insurance negotiations resulted in a substantial price cut for the three domestic broad-spectrum anti-cancer drugs PD-1 monoclonal antibodies to enter the medical insurance.
Not only did the profits of domestic bid-winning companies' generic drugs fall off a cliff, especially for a large number of entrepreneurial biosimilars and similar drugs that are still in the research and development stage.
Enterprises sounded the alarm.
However, in order to promote the truly innovative development of the pharmaceutical industry and improve the international competitiveness of domestic drugs, the state began to implement centralized procurement and medical insurance negotiations at the end of 2018, completely subverting the operation model of the imitation and innovative drug market in China’s pharmaceutical industry, especially at the end of December 2020.
Medical insurance negotiations resulted in a substantial price cut for the three domestic broad-spectrum anti-cancer drugs PD-1 monoclonal antibodies to enter the medical insurance.
Not only did the profits of domestic bid-winning companies' generic drugs fall off a cliff, especially for a large number of entrepreneurial biosimilars and similar drugs that are still in the research and development stage.
Enterprises sounded the alarm.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Recently, the National Health Commission and others have issued the "Guiding Opinions on Further Regulating Medical Behaviors and Promoting Reasonable Medical Examinations.
" The National Health Commission will organize the formulation of national clinical diagnosis and treatment guidelines, clinical technical operating specifications, rational drug use guidelines, clinical pathways, etc.
, This means that drugs that have not entered the clinical pathway may be eliminated on a large scale.
Recently, the National Health Commission and others have issued the "Guiding Opinions on Further Regulating Medical Behaviors and Promoting Reasonable Medical Examinations.
" The National Health Commission will organize the formulation of national clinical diagnosis and treatment guidelines, clinical technical operating specifications, rational drug use guidelines, clinical pathways, etc.
, This means that drugs that have not entered the clinical pathway may be eliminated on a large scale.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>All this shows that the pharmaceutical industry is dominated by imitation, and uses price as a means of competition.
If companies lacking original innovative drug research capabilities do not transform to truly innovate First-in-class drug research and development, they will not only not be able to compete in the international market, but also in the domestic market.
There will be no chance of survival, which means that only companies that can compete in the international market can develop in the domestic market .
All this shows that the pharmaceutical industry is dominated by imitation, and uses price as a means of competition.
If companies lacking original innovative drug research capabilities do not transform to truly innovate First-in-class drug research and development, they will not only not be able to compete in the international market, but also in the domestic market.
There will be no chance of survival, which means that only companies that can compete in the international market can develop in the domestic market .
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>It is very necessary and important for generic drugs to benefit more patients at low prices.
The original innovative drugs can give domestic pharmaceutical companies the strength to participate in international and domestic competition and make greater contributions to human health, which is also indispensable.
It is very necessary and important for generic drugs to benefit more patients at low prices.
The original innovative drugs can give domestic pharmaceutical companies the strength to participate in international and domestic competition and make greater contributions to human health, which is also indispensable.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>But we can't help asking: How should Chinese innovative drugs, especially biopharmaceuticals, proceed? How should enterprises transform?But we can't help asking: How should Chinese innovative drugs, especially biopharmaceuticals, proceed? How should enterprises transform?544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>02 Can't expect Fast follow strategy to form long-term competitive advantage and brand02 Can't expect Fast follow strategy to form long-term competitive advantage and brand 02 Can't expect Fast follow strategy to form long-term competitive advantage and brand544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>With the rapid advancement of biopharmaceutical technology in my country, the pace of drug innovation has been rapid in recent years.
The time point for the follow-up of Fast follow has moved from pre-marketed drugs to phase II, phase III, and even preclinical phases, and the number of competitors has also increased.
From a few previous companies to more than a dozen companies, a batch of Me-too and Me-better varieties and enterprises have also been established (there are examples of successful license-out).
With the rapid advancement of biopharmaceutical technology in my country, the pace of drug innovation has been rapid in recent years.
The time point for the follow-up of Fast follow has moved from pre-marketed drugs to phase II, phase III, and even preclinical phases, and the number of competitors has also increased.
From a few previous companies to more than a dozen companies, a batch of Me-too and Me-better varieties and enterprises have also been established (there are examples of successful license-out).
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>But Fast follow only moves the imitation forward, and is still the same target as foreign drugs.
From the perspective of the Claudin 18.
2 target, Astellas is clearly First-in-class and is in Phase III; however, there have been nearly 20 local pharmaceutical companies under research in China, many of which have entered Phase I, and there are monoclonal antibodies in the research project category.
, Double antibodies, ADC and even CAR-T.
A similar situation also appeared on the PD-L1/TGF-β, Trop 2-ADC track.
 But Fast follow only moves the imitation forward, and is still the same target as foreign drugs.
From the perspective of the Claudin 18.
2 target, Astellas is clearly First-in-class and is in Phase III; however, there have been nearly 20 local pharmaceutical companies under research in China, many of which have entered Phase I, and there are monoclonal antibodies in the research project category.
, Double antibodies, ADC and even CAR-T.
A similar situation also appeared on the PD-L1/TGF-β, Trop 2-ADC track.
 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The technology introduction and innovation platforms for gene therapy established in various parks are similar.
In addition, the introduction of innovations such as Fast follow CAR-T cell therapy has been very hot in domestic clinical trials.
As of the end of June 2020, there are a total of 670 CAR-T clinical trials in progress worldwide, and China currently ranks first in the world with 357 CAR-T clinical trials.
Patients and society have no idea how to afford the “astronomical price” of millions of RMB.
The industry also believes that “the domestic medical insurance is unrealistic to pay for CAR-T.
” Such innovative drugs cannot be compared to foreign companies.
Possibility to reduce prices.
The technology introduction and innovation platforms for gene therapy established in various parks are similar.
In addition, the introduction of innovations such as Fast follow CAR-T cell therapy has been very hot in domestic clinical trials.
As of the end of June 2020, there are a total of 670 CAR-T clinical trials in progress worldwide, and China currently ranks first in the world with 357 CAR-T clinical trials.
Patients and society have no idea how to afford the “astronomical price” of millions of RMB.
The industry also believes that “the domestic medical insurance is unrealistic to pay for CAR-T.
” Such innovative drugs cannot be compared to foreign companies.
Possibility to reduce prices.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>It should be noted that large-scale or original pharmaceutical companies in Europe, America, and Japan also distinguish their advantages in different fields.
In the long-term operation process, these companies have established a dominant position in a certain field through their own innovative research and development, corporate mergers and acquisitions, project purchases and other modes: such as focusing on immunity, cardiovascular, and anti-tumor, such as Moderna's mRNA vaccine against viral infections.
Sexual disease. It should be noted that large-scale or original pharmaceutical companies in Europe, America, and Japan also distinguish their advantages in different fields.

In the long-term operation process, these companies have established a dominant position in a certain field through their own innovative research and development, corporate mergers and acquisitions, project purchases and other modes: such as focusing on immunity, cardiovascular, and anti-tumor, such as Moderna's mRNA vaccine against viral infections.
Sexual disease. 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>For domestic pharmaceutical companies to participate in global competition, it is best not to expect to surpass traditional large-scale international pharmaceutical companies from the very beginning.
Because talents are equal, our talents cannot take all innovative ideas into the world.
They each play an innovative and leading role in the field of focus, and form their own advantages in the market during the development process.
This is the essence of competition.
For domestic pharmaceutical companies to participate in global competition, it is best not to expect to surpass traditional large-scale international pharmaceutical companies from the very beginning.
Because talents are equal, our talents cannot take all innovative ideas into the world.
They each play an innovative and leading role in the field of focus, and form their own advantages in the market during the development process.
This is the essence of competition.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>In order to innovate, on the one hand, we must strengthen basic research, and we must also realize that basic discoveries cannot be automatically transformed into applied innovation.
Biopharmaceuticals are the application of molecular biology in the pharmaceutical industry.
It is a new trend in the development of the pharmaceutical industry.
It has already brought huge benefits to patients in the fields of anti-tumor and immunological disease treatment.
Therefore, it is necessary to be far-sighted and forward-looking in this direction.
layout.
In order to innovate, on the one hand, we must strengthen basic research, and we must also realize that basic discoveries cannot be automatically transformed into applied innovation.
Biopharmaceuticals are the application of molecular biology in the pharmaceutical industry.
It is a new trend in the development of the pharmaceutical industry.
It has already brought huge benefits to patients in the fields of anti-tumor and immunological disease treatment.
Therefore, it is necessary to be far-sighted and forward-looking in this direction.
layout.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The first thing to be clear is that it hasn't been long for major pharmaceutical countries such as Europe, America and Japan to transform biopharmaceuticals.
Over the years of reform and opening up, the number of basic and applied biology talents studying abroad in high-level universities abroad has been sufficient, and they have mastered the most advanced technologies.
Our country is not far behind in technology.
The key is how to integrate these technologies with the research and development of new drugs.
.
It is entirely possible for Chinese companies to form competitive advantages and brands in certain disease treatment fields by keeping abreast on the biopharmaceutical track, competing on the higher levels of First in class and Best in class drugs, and obtaining marketing authorization in the international regulated market to participate in global competition.
of.
The first thing to be clear is that it hasn't been long for major pharmaceutical countries such as Europe, America and Japan to transform biopharmaceuticals.
Over the years of reform and opening up, the number of basic and applied biology talents studying abroad in high-level universities abroad has been sufficient, and they have mastered the most advanced technologies.
Our country is not far behind in technology.
The key is how to integrate these technologies with the research and development of new drugs.
.
It is entirely possible for Chinese companies to form competitive advantages and brands in certain disease treatment fields by keeping abreast on the biopharmaceutical track, competing on the higher levels of First in class and Best in class drugs, and obtaining marketing authorization in the international regulated market to participate in global competition.
of.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>03 The research and development of original biopharmaceuticals must conform to the trend of the times, break through old concepts, and open up new ideas03 The research and development of original biological drugs must conform to the trend of the times, break through the old concepts, and open up new ideas 03 The research and development of original biological drugs must conform to the trend of the times, break through the old concepts, and open up new ideas544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The development of the pharmaceutical industry must abandon old concepts, conform to the historical trend, and adapt to the reality of scientific and technological development.
It also requires a fearless spirit of innovation.
Even in innovative fields such as biopharmaceuticals, if there is no originality, it can only imitate and track drugs from advanced developed countries such as the United States.
That way, the pattern of the pharmaceutical industry will never be changed.
The development of the pharmaceutical industry must abandon old concepts, conform to the historical trend, and adapt to the reality of scientific and technological development.
It also requires a fearless spirit of innovation.
Even in innovative fields such as biopharmaceuticals, if there is no originality, it can only imitate and track drugs from advanced developed countries such as the United States.
That way, the pattern of the pharmaceutical industry will never be changed.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The choice of target is the first step in the development of original drugs.
Although basic research institutes continue to provide drug targets for biopharmaceutical research and development, most of their own innovative targets in the past have not been recognized by research and industry, and the mechanism of drug targets is not highly recognized.
Drugs developed with these targets are not Did not show the therapeutic effect it should have.
The choice of target is the first step in the development of original drugs.
Although basic research institutes continue to provide drug targets for biopharmaceutical research and development, most of their own innovative targets in the past have not been recognized by research and industry, and the mechanism of drug targets is not highly recognized.
Drugs developed with these targets are not Did not show the therapeutic effect it should have.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>However, the development of the times has brought advances in science and technology, especially new ideas for the research and development of biopharmaceuticals.
In the past, undeveloped targets or drugs that could not be developed for other reasons can become new ideas for original drug development as technology advances.
The research and development of this original drug is a bonus brought about by the progress of the times.
There is a time window and a certain range, after which the competition will be fierce.
Therefore, forward-looking thinking and layout are especially important.
However, the development of the times has brought advances in science and technology, especially new ideas for the research and development of biopharmaceuticals.
In the past, undeveloped targets or drugs that could not be developed for other reasons can become new ideas for original drug development as technology advances.
The research and development of this original drug is a bonus brought about by the progress of the times.
There is a time window and a certain range, after which the competition will be fierce.
Therefore, forward-looking thinking and layout are especially important.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Briefly introduce the new mechanisms of several innovative biological drugs and the research and development ideas of innovative drugs:Briefly introduce the new mechanisms of several innovative biological drugs and the research and development ideas of innovative drugs:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Drugs can choose their own targets (targeted biological drugs).
For example, proteins that were not medicines in the past and played an important role in the development of diseases can be targeted for degradation with modern technology, similar to targeting CAR-T cells.
Drugs can choose their own targets (targeted biological drugs).
For example, proteins that were not medicines in the past and played an important role in the development of diseases can be targeted for degradation with modern technology, similar to targeting CAR-T cells.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>The new crown virus reminds us that there are still no medicines for the diseases caused by many viruses, such as AIDS and hepatitis B.
In fact, the human body can produce antibodies that neutralize the virus, but in the past, antibodies could not be produced and only screening was used to treat diseases with antisera.
Recently, the production technology of monoclonal antibodies has made a leap, and the production of humanized antibodies as biological drugs has become an important means for the treatment of this type of disease.
The new crown virus reminds us that there are still no medicines for the diseases caused by many viruses, such as AIDS and hepatitis B.
In fact, the human body can produce antibodies that neutralize the virus, but in the past, antibodies could not be produced and only screening was used to treat diseases with antisera.
Recently, the production technology of monoclonal antibodies has made a leap, and the production of humanized antibodies as biological drugs has become an important means for the treatment of this type of disease.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>In the past, many diseases caused by protein function changes caused by gene mutations did not have treatments.
Now gene therapy provides a means for the treatment of these diseases.
For example, CRISPR/Cas9 can modify gene therapy for this disease.
Even with more complex protein mutations, gene carriers can be used to express healthy proteins in the body, replacing the function of disease-curing proteins for gene therapy of such diseases.
In the past, many diseases caused by protein function changes caused by gene mutations did not have treatments.
Now gene therapy provides a means for the treatment of these diseases.
For example, CRISPR/Cas9 can modify gene therapy for this disease.
Even with more complex protein mutations, gene carriers can be used to express healthy proteins in the body, replacing the function of disease-curing proteins for gene therapy of such diseases.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Cardiovascular and cerebrovascular diseases are major chronic diseases that threaten human health.
However, it is unpopular to make original cardiovascular biological drugs and can only fight alone; the advantage is that the track is empty and there are few competitors.
It is worth mentioning that thrombotic cardiovascular and cerebrovascular diseases kill at least 15 million people every year (the data released by WHO in 2016), and there are about 3 million people in our country.
Obviously, thrombotic cardiovascular and cerebrovascular diseases are the biggest unmet patient needs.
Cardiovascular and cerebrovascular diseases are major chronic diseases that threaten human health.
However, it is unpopular to make original cardiovascular biological drugs and can only fight alone; the advantage is that the track is empty and there are few competitors.
It is worth mentioning that thrombotic cardiovascular and cerebrovascular diseases kill at least 15 million people every year (the data released by WHO in 2016), and there are about 3 million people in our country.
Obviously, thrombotic cardiovascular and cerebrovascular diseases are the biggest unmet patient needs.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>If we can differentiate and develop these original biological drugs with great impact, we will certainly be able to establish a comparative advantage in global competition in the development of drugs in certain disease treatment fields.
Companies with high-quality drugs will gain credibility over time.
There will be brands.
If we can differentiate and develop these original biological drugs with great impact, we will certainly be able to establish a comparative advantage in global competition in the development of drugs in certain disease treatment fields.
Companies with high-quality drugs will gain credibility over time.
There will be brands.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Recently, the State-owned Assets Supervision and Administration Commission announced that breakthroughs in major scientific and technological innovation projects will be included in the performance evaluation of central enterprises, and the scientific research investment of central enterprises will be evaluated as profits, and central enterprises will be encouraged to invest most of the state-owned capital operating budgets in scientific and technological innovation.
Recently, the State-owned Assets Supervision and Administration Commission announced that breakthroughs in major scientific and technological innovation projects will be included in the performance evaluation of central enterprises, and the scientific research investment of central enterprises will be evaluated as profits, and central enterprises will be encouraged to invest most of the state-owned capital operating budgets in scientific and technological innovation.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>Capital is one side of the original innovation medal, and the other side is the innovative thinking of those real talents, not those academic titles.
I hope that these measures will bring an infinitely bright future to the motherland.
Capital is one side of the original innovation medal, and the other side is the innovative thinking of those real talents, not those academic titles.
I hope that these measures will bring an infinitely bright future to the motherland.